Century Therapeutics, INC DEF 14A proxy statements

Century Therapeutics has filed its 2026 proxy statement, outlining director elections, auditor ratification, and a proposal to increase authorized common stock.

Century Therapeutics, Inc. will hold a special meeting on January 22, 2026, to vote on a reverse stock split ranging from 1-for-5 to 1-for-30.

Century Therapeutics, Inc. is calling a Special Meeting of Stockholders on January 22, 2026, to vote on a reverse stock split to maintain its Nasdaq listing.

Century Therapeutics will hold its annual stockholder meeting on June 12, 2025, to elect Class I directors and ratify the appointment of Ernst & Young LLP as its independent auditor.

Century Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 12, 2025, to vote on director elections and the ratification of its accounting firm.

Century Therapeutics is holding its annual meeting on June 20, 2024, seeking shareholder votes on key proposals including director elections, auditor ratification, and an amendment to limit officer liability.

Century Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 20, 2024, featuring proposals for director elections, auditor ratification, and corporate governance amendments.